1. Huang GS, Arend RC, Li M, Gunter MJ, Chiu LG, Horwitz SB, Goldberg GL. “Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.” Am J Obstet Gynecol. 2009 Apr; 200(4): 457.e1-457.e5. PMID: 19200930
  • Huang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL. “Extragenital adenosarcoma: a case report, review of the literature, and management discussion.” Gynecol Oncol. 2009 Dec; 115(3): 472-475. PMID: 19712965
  • Arend RC, Holland A, St Clair C, Herzog TJ. “Fertility preservation in ovarian cancer.” Therapy. 2010 May; 7(3): 257-267.
  • Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, Goldberg GL, Smith HO. “Co-expression of GPR30 and ERb and their association with disease progression in uterine carcinosarcoma.” Am J Obstet Gynecol. 2010 Sept; 203(3): 242.e1-242.e5. PMID: 20605134
  • Arend RC, Bagaria M, Lewin SN, Sun X, Deutsch I, Burke WM, Herzog TJ, Wright JD. “Long-term outcome and natural history of uterine adenosarcomas.” Gynecol Oncol. 2010 Nov; 119(2): 305-308. PMID: 20688363
  • Arend RC,Doneza JA, Wright JD.  “Uterine carcinosarcoma.” Curr Opin Oncol. 2011 Sep; 23(5): 531-536. PMID: 21743326
  • Wright JD, Herzog TJ, Siddiq Z, Arend RC, Neugut AI, Burke WM, Lewin SN, Ananth C, Hershman DL. “Failure to rescue as a source of variation in hospital mortality for ovarian cancer.” J Clin Oncol. 2012 Nov; 30(32): 3976-82. PMID: 23032619
  • Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD. “Folate and folate receptor alpha antagonists, mechanism of action in ovarian cancer.” Gynecol Oncol.2013 Nov; 131(2): 493-498. PMID: 23863359
  • Arend RC, Londoño-Joshi A, Straughn JM, Buchsbaum DJ. “The Wnt/ß-catenin pathway in ovarian cancer: A review.” Gynecol Oncol. 2013 Dec;131(3): 772-778. PMID: 2415749
  1.  Londoño-Joshi A*Arend RC* (joint first authors), Aristizabal L, Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M, Forero-Torres A, LoBuglio AF, Li Y, Buchsbaum DJ. “Effect of niclosamide on basal-like breast cancers.” Mol Cancer Ther.2014 Apr; 13(4): 800-11. PMID: 24552774
  1.  Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Landen CN, Alvarez R, Straughn M, Buchsbaum DJ. “Inhibition of Wnt/ß-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.” Gynecol Oncol. 2014 Jul; 134(1): 112-120. PMID: 24736023
  1.  Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. “Multi-targeted therapy of cancer by niclosamide: a new application for an old drug.” Cancer Lett.  2014 Jul; 349(1):8-14. PMID: 24732808
  1. Doo D, Erickson BK, Arend RC, Conner MG, Huh WK, Leath C. “Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma.” Gynecol Oncol. 2014 May; 133(2):234-7. PMID: 24631447
  1.  Walters Haygood C, Arend RC, Straughn JM, Buchsbaum DJ.  “Ovarian cancer stem cells: can targeted therapy lead to improved progression-free survival?”World J Stem Cells. 2014 Sep; 26;6(4):441-7. PMID: 25258665
  1.  Walters Haygood CL, Arend RC, GangradeA, Li P-K, Ph.D., Li Y, Straughn JM, Buchsbaum DJ. “Niclosamide analogs for treatment of ovarian cancer.” Int J Gynecol Cancer. 2015; Oct 25(8):1377-85. PMID: 26186072
  1.  Smith HJ, Walters Haygood CL, Arend RC, Leath III CA, Straughn JM “PARP inhibitors as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: can we afford it?” Gynecol Oncol. 2015 Oct; 139(1):59-62. PMID: 26303225
  1.  Boone JD, Arend RC, Cooper SJ, Gilchrest A, Oelschlager DK, Grizzle WE,McGwin G, Abhishek G, Straughn JM, Buchsbaum DJ. “Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.” Lab Invest. 2016 Feb; 96(2):249-59. PMID: 26658453
  1.  Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, Yoon K, Klug CA, Bullard DC, Kesterson RA, Conner MG, Oliver PG, Arend RC, O’Conner AK, Yoder BK, Bellis SL. “The  tumor-associated glycosyltransferase, ST6Gal-I, regulates expression of key stem cell transcription factors and  confers a cancer stem cell phenotype.” Cancer Research.2016 July 1; 76(13): 1-11. PMID: 27216178
  1.  Turner TB, Buchsbaum DJ, Straughn JM, Randall TD, Arend RC. “Ovarian cancer and the immune system – The role of targeted therapies.” Gynecol Oncol. 2016 Aug; 142(2):349-56. PMID: 27174875
  •  Craig ER, Londoño-Joshi AI, Norian LA, Arend RC.Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A systematic review.” Gynecol Oncol.2016 Dec; 143(3):674-683. PMID: 27751590
  •  Arend RC, Londoño-Joshi AI, Gangrade A, Jatre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ. “Niclosamide and  its derivatives are potent inhibitors of WNT/b-catenin, mTOR and STAT3 signaling in ovarian cancer.” Oncotarget.2016 Dec 27; 7(52):86803-86815. PMID: 27888804
  •  Smith HJ, Straughn JM, Buchsbaum DJ, Arend RC. “Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.” Gynecol Oncol Rep.2017 Mar 21;20:81-86. PMID: 28378010
  •  Kasten BB, Arend RC,Katre AA, Kim H, Fan J, Ferrone, S, Zinn KR, Buchsbaum DJ.  “B7-H3-  targeted Pb212 radioimmunotherapy of ovarian cancer in preclinical models.”  Nucl Med Biol. 2017 Apr;47:23-30. PMID: 28104527
  •  Harada S, Arend RC, Dai Q, Levesque J, Winokur TS, Gu RG, Heslin MJ, Nabell L, Nabors LB, , Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES.  “The Molecular Tumor Board: A Two-year Experience at the University of Alabama at Birmingham.” Oncotarget.2017Jun 14; 8(34):  57845-57854. PMID: 28915716
  •  Turner TB, Meza-Perez S, Londono A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Buchsbaum DJ, Straughn JM, Randall T, Arend RC. “Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.” Oncotarget.2017 Jul 4; 8(27): 44159-44170. PMID: 28498806
  •  Chen X, Arend RC, Hamele-Bene D, Tergas A, Hawver M, Tong G, Wright TC, Wright JD.  “Uterine Carcinomas: clinical histopathological and immunohistochemical characteristics.” International Journal of Gynecological Pathology. 2017 Sept; 36(5) 412-419. PMID: 28700424
  •  Bayley AJ, Sooryanarayana V, Arend RC.“Histone Methyltransferase EZH2: A therapeutic target for ovarian cancer.” Mol Cancer Ther. 2018 Mar;17(3):591-602. (Editor’s Pick) PMID: 29726819
  •  Arend RC*, Van Arsdale AR*, Cossio MJ, Erickson BK, Wang Y, Doo DW, Leath CA, Goldberg GL, Huang GS.  “Insulin-Like Growth Factor 2: A Poor Prognostic Biomarker Linked to Racial Disparity in Women with Uterine Carcinosarcoma.” Cancer Medicine 2018; 7(3):616-625. PMID 29455465 (*co-first authors)
  • Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd.  “Molecular Response to Neoadjuvant chemotherapy in High-Grade Serous Ovarian Carcinoma.” Molecular Cancer Research. March 9, 2018, 1158/1541-7786. MCR-17-0594. PMID: 29523763
  • McCaw TR, Randall TR, Arend, RC.Overcoming immune suppression with epigenetic modification in ovarian cancer.” Translational Research. 2018 Jun 23. pii: S1931-5244(18)30099-9. PMID: 30048638
  • Arend RC, Toboni MD, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, Herzog TJ. “Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.” Oncologist. 2018 Aug 23. pii: theoncologist.2018-0095. PMID:30139839
  • Cohen CW, Fontaine KR, Arend RC, Soleymani T, Gower BA.  “Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: A randomized, controlled trial.” Nutrients. 2018 Aug 30; 10(9). pii: E1187. PMID:30200193
  • Wu J, Blair J, Izevbigie OC, Wright NC, Arend RC.Disparities in receipt of follow-up care instructions among female adult cancer survivors: results from a national survey.” Gynecol Oncol. 2018 Sep; 150(3):494-500. PMID: 29970241
  • Arend RC, Jones BA, Martinez A, Goodfellow P. “Endometrial cancer: Molecular markers and management of advanced stage disease.”  Gynecol Oncol.2018 Sep; 150(3):569-580. PMID: 29843906
  • McCaw TR, Mei L, Starenki D, Cooper SJ, Liu M, Meza-Perez S, Arend RC,Buchsbaum DJ, Forero A, Randall TD. “The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.” Cancer Immunol Immunother. 2018 Oct 17. doi: 10.1007/s00262-018-2262-5. [Epub ahead of print] PMID: 30334128
  • Kreitzburg KM, Fehling SC, Landen CN, Gamblin TL, Vance RB, Arend RC, Katre AA, Oliver PG, Van Waardenburg RC, Alvarez RD, Yoon KJ. “FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.”  Cancer Letters.Volume 436, 2018 Nov. 1; 75-86. PMID: 30120964
  • Kreitzburg KM, Landen CN, Gamblin TL, Katre AA, Arend RC, Oliver PG, Council LN, Waardenburg RCAM, Alvarez RD, Yoon KJ “FTY720 enhances the anti-tumor activity of carboplatin, paclitaxel, and tamoxifen in models of drug-resistant ovarian cancer” Mol Cancer Ther. 2018 Nov 1. PMID: 30120964
  • Cohen CW, Fontaine KR, Arend RC, Alvarez RD, Leath III CA, Huh WK, Bevis KS, Kim KH, Straughn Jr. JM, Gower BA. “A ketogenic diet reduces central obesity and insulin in women with ovarian or endometrial cancer.” The Journal of Nutrition.Volume 148, Issue 8, page 1253-1260. PMID: 30137481
  • Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Straughn JM Jr, Norian LA, Arend RC. “The anti-tumor effects of entinostat in ovarian cancer require adaptive immunity.” Cancer. 2018 Dec 15;124(24):4657-4666. PMID: 30423192
  • McCaw TR, Randall TD, Arend RC. “Revisiting entinostat as an immune-potentiating adjuvant” Oncotarget. 2018 Dec 18. PMID: 30647864
  • Roane B, Arend RC, Birrer M. “Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer” Cancers. 2019 May 11. PMID: 31091744
  • Barksdale E, Beaver J, Coleman R, Arend RC, Armstrong D, Bala S, Mills G, Sood A, Herzog T.  “Advancing Drug Development in Gynecologic Malignancies” Clinical Cancer Research. 2019 May 24. PMID: 31126961
  • Goldsberry WN, Londono AI, Randall TD, Norian LA, Arend RC. “A Review of the Role of Wnt in Cancer Immunomodulation” Cancers. 2019 Jun 4. PMID: 31167446
  • Doo DW, Norian LA, Arend RC. “Checkpoint inhibitors in ovarian cancer: A review of preclinical data” Gynecol Oncol Rep. 2019 Jun 19. PMID: 31312712
  • Cohen CW, Fontaine KR, Arend RC,Gower BA. “A Ketogenic Diet is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: A Randomized, Controlled Trial” Nutrition and Cancer. 2019 Jul 27. PMID: 31352797
  • Dockery LE, RubensteinAR, Ding K, MashburnSG, BurkettWC, MD, MontgomeryA, Doo DW, Arend RC, Moore KN,Gunderson CC. “Extending the Platinum-Free Interval: The Impact of Omitting 2nd Line Platinum Chemotherapy in Intermediate Platinum-Sensitive Ovarian Cancer”  Gynecol Oncol. 2019 Sep 12. PMID: 31522837
  • Arend RC, Van Arsdale A, Gojayev A, Roane BM, Doo DW, Leath CA, Goldberg GL, Huang G. “Neutrophilia and mortality in women with uterine carcinosarcoma” Int J Gynecol Cancer. 2019 Oct 29. PMID: 31320488
  • Arend RC, Weston S, Coleman R. “Decision analysis for second-line maintenance therapy of platinum-sensitive recurrent ovarian cancer: a review”  Int J Gynecol Cancer.2020 Feb 19. PMID: 32079709
  • Pier B, Crellin C, Katre A, Young SL, Bates GW, Arend RC.Intramural Leiomyomas Decrease Leukemia Inhibitory Factor in the Secretory Phase” Reproductive Science. In Press.
  • Doo D, Meza-Perez S, Londono A, Katre A, Boone J, Moore D, Hudson C, Betella I, McCaw T, Gangrade A, Bao R, Luke J, Yang E, Birrer M, Starenki D, Cooper S, Buchsbaum D, Norian LA, Randall TD, Arend RC.  “Inhibition of the Wnt/β-catenin pathway enhances anti-tumor immunity in ovarian cancer.” Cancer Immunology Research.Manuscript accepted.
  • McCaw TR, Li M, Starenki D, Liu M, Cooper SJ, Arend RC, Forero A, Buchsbaum DJ, Randall TD. “Histone deacetylase inhibition promotes intratumoral CD8+ T Cell responses, sensitizing murine breast tumors to anti-PD1.” Cancer Immunol, Immunother. 2019 Nov 12.PMID: 31720815
  • Boi SK, Orlandella RM, Gibson JT, Turbitt WJ, Wald G, Thomas L, Rosean CB,  Norris KE, Bing M, Bertrand L, Gross BP, Makkouk A, Starenki D, Sorge RE, Brown JA, Gordetsky J, Yasin H, Garge R, Nandagopal L, Weiner GJ, Lubaroff D, Arend RC, Li P, Zakharia Y, Yang ES,  Salem A, Nepple K, Marquez-Lago TT, Norian LA. “Obesity diminishes response to PD-1-based immunotherapies in renal cancer.”  Journal of Clinical Investigation. Manuscript Submitted.
  • Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Minei TR, Harats D, Wall JA, Foxall ME, Penson RT. “Ofranergene Obadenovec (VB-111) in Platinum-resistant Ovarian cancer; Favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.” Gynecol Oncol. Manuscript accepted.
  • Arend RC, Fisher AJ, Chou J, Jacobs I, Monk BJ. “Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease.” Critical Reviews in Oncology/Hematology. Manuscript submitted.
  • Wall JA, Arend RC. “Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer.” Ann Transl Med. Manuscript accepted.
  • McCaw TR, Brooke D, Goel N, Katre AA, Londono AI, Turner TB, Smith HJ, Randall TD, Arend RC. “Compromising immunosuppressive networks using class I histone deacetylase inhibition promotes CD8 T cell response in ovarian cancer.” Cancer. Manuscript submitted.